Top

Journal of Neuro-Oncology

Published in:

01-02-2019 | Topic Review

5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas

Authors: Muhammad Omar Chohan, Mitchel S. Berger

Published in: Journal of Neuro-Oncology | Issue 3/2019

Abstract

Introduction

Fluorescence guided surgery (FGS) with five-aminolevulinic acid (5-ALA) is expected to revolutionize neurosurgical care of patients with high-grade gliomas (HGG). After the recent landmark FDA approval, this optical agent is now available to neurosurgeons in the United States.

Methods

This review is designed to highlight the evidence for the use of 5-ALA in recurrent HGG surgery for the neurosurgical community. The manuscript was prepared in accordance with the PRISMA guidelines.

Results

Intra-operatively, a strong fluorescent signal is highly correlated with the presence of cellular tumor in recurrent HGG, giving it a high positive predictive value (PPV). Similar to what is observed in primary HGG surgery, false-negative results can occur if tumor cells do not emit fluorescence. In addition, false-positive fluorescence signals in tissues devoid of tumor cells can be observed more frequently in recurrent HGG compared to the primary setting. However, these areas overwhelmingly contain reactive/regressive tissue, resection of which is unlikely to cause functional deficits. The safety profile of 5-ALA is similarly favorable in primary and recurrent HGG.

Conclusions

5-ALA FGS is a powerful adjunct in the resection of recurrent HGG with a high PPV and favorable safety profile. It is therefore the authors’ opinion to routinely employ this fluorescent agent as a standard of care.

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. https://doi.org/10.3171/2011.2.JNS10998 CrossRefPubMed

Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, Ashby LS, Brachman D, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2014) An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg 120:846–853. https://doi.org/10.3171/2013.12.JNS13184 CrossRefPubMed

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, Group AL-GS (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. https://doi.org/10.1016/S1470-2045(06)70665-9 CrossRefPubMed

Lau D, Hervey-Jumper SL, Chang S, Molinaro AM, McDermott MW, Phillips JJ, Berger MS (2016) A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. J Neurosurg 124:1300–1309. https://doi.org/10.3171/2015.5.JNS1577 CrossRefPubMed

Widhalm G, Minchev G, Woehrer A, Preusser M, Kiesel B, Furtner J, Mert A, Di Ieva A, Tomanek B, Prayer D, Marosi C, Hainfellner JA, Knosp E, Wolfsberger S (2012) Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. Neurosurg Rev 35:381–391. https://doi.org/10.1007/s10143-012-0374-5 CrossRefPubMed

Nabavi A, Thurm H, Zountsas B, Pietsch T, Lanfermann H, Pichlmeier U, Mehdorn M, Group ALARGS (2009) Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 65:1070–1076. https://doi.org/10.1227/01.NEU.0000360128.03597.C7 (discussion 1076–1077)CrossRefPubMed

Utsuki S, Oka H, Sato S, Shimizu S, Suzuki S, Tanizaki Y, Kondo K, Miyajima Y, Fujii K (2007) Histological examination of false positive tissue resection using 5-aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir 47:210–213 (discussion 213–214)CrossRef

Kamp MA, Grosser P, Felsberg J, Slotty PJ, Steiger HJ, Reifenberger G, Sabel M (2012) 5-Aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir (Wien) 154:223–228. https://doi.org/10.1007/s00701-011-1200-5 (discussion 228)CrossRef

Parvez K, Parvez A, Zadeh G (2014) The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci 15:11832–11846. https://doi.org/10.3390/ijms150711832 CrossRefPubMedPubMedCentral

10.

Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377–384. https://doi.org/10.1148/radiology.217.2.r00nv36377 CrossRefPubMed

11.

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461. https://doi.org/10.1016/S1470-2045(08)70125-6 CrossRefPubMed

12.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269CrossRef

13.

Hoover JM, Nwojo M, Puffer R, Mandrekar J, Meyer FB, Parney IF (2013) Surgical outcomes in recurrent glioma clinical article. J Neurosurg 118:1224–1231. https://doi.org/10.3171/2013.2.Jns121731 CrossRefPubMed

14.

Schucht P, Knittel S, Slotboom J, Seidel K, Murek M, Jilch A, Raabe A, Beck J (2014) 5-ALA complete resections go beyond MR contrast enhancement: shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma. Acta Neurochir (Wien) 156:305–312. https://doi.org/10.1007/s00701-013-1906-7 (discussion 312)CrossRef

15.

Della Puppa A, Ciccarino P, Lombardi G, Rolma G, Cecchin D, Rossetto M (2014) 5-Aminolevulinic acid fluorescence in high grade glioma surgery: surgical outcome, intraoperative findings, and fluorescence patterns. Biomed Res Int 2014:232561. https://doi.org/10.1155/2014/232561 CrossRefPubMed

16.

Idoate MA, Valle RD, Echeveste J, Tejada S (2011) Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 31:575–582. https://doi.org/10.1111/j.1440-1789.2011.01202.x CrossRefPubMed

17.

Tonn JC, Stummer W (2008) Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. Clin Neurosurg 55:20–26PubMed

18.

Stummer W, Tonn JC, Goetz C, Ullrich W, Stepp H, Bink A, Pietsch T, Pichlmeier U (2014) 5-Aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery 74:310–319. https://doi.org/10.1227/Neu.0000000000000267 CrossRefPubMed

19.

Hickmann AK, Nadji-Ohl M, Hopf NJ (2015) Feasibility of fluorescence-guided resection of recurrent gliomas using five-aminolevulinic acid: retrospective analysis of surgical and neurological outcome in 58 patients. J Neuro-oncol 122:151–160. https://doi.org/10.1007/s11060-014-1694-9 CrossRef

20.

Kamp MA, Felsberg J, Sadat H, Kuzibaev J, Steiger HJ, Rapp M, Reifenberger G, Dibue M, Sabel M (2015) 5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. Acta Neurochir (Wien) 157:207–213. https://doi.org/10.1007/s00701-014-2313-4 (discussion 213–204)CrossRef

21.

Wachter D, Kallenberg K, Wrede A, Schulz-Schaeffer W, Behm T, Rohde V (2012) Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue? J Neurol Surg A 73:401–406. https://doi.org/10.1055/s-0032-1304810 CrossRef

22.

Tykocki T, Michalik R, Bonicki W, Nauman P (2012) Fluorescence-guided resection of primary and recurrent malignant gliomas with 5-aminolevulinic acid. Preliminary results. Neurol Neurochir Pol 46:47–51CrossRef

23.

Hefti M, von Campe G, Moschopulos M, Siegner A, Looser H, Landolt H (2008) 5-Aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institutuion. Swiss Med Wkly 138:180–185PubMed

24.

Panciani PP, Fontanella M, Garbossa D, Agnoletti A, Ducati A, Lanotte M (2012) 5-Aminolevulinic acid and neuronavigation in high-grade glioma surgery: results of a combined approach. Neurocirugia (Astur) 23:23–28. https://doi.org/10.1016/j.neucir.2012.04.003 CrossRef

25.

Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:1003–1013. https://doi.org/10.3171/jns.2000.93.6.1003 CrossRefPubMed

26.

Dietze A, Berg K (2005) ALA-induced porphyrin formation and fluorescence in synovitis tissue in-vitro and in vivo studies. Photodiagn Photodyn Ther 2:299–307. https://doi.org/10.1016/S1572-1000(05)00107-9 CrossRef

27.

Dietel W, Bolsen K, Dickson E, Fritsch C, Pottier R, Wendenburg R (1996) Formation of water-soluble porphyrins and protoporphyrin IX in 5-aminolevulinic-acid-incubated carcinoma cells. J Photochem Photobiol B 33:225–231. https://doi.org/10.1016/1011-1344(95)07249-7 CrossRefPubMed

28.

Polo CF, Frisardi AL, Resnik ER, Schoua AEM, Batlle AMD (1988) Factors influencing fluorescence-spectra of free porphyrins. Clin Chem 34:757–760PubMed

29.

Valle RD, Solis ST, Gastearena MAI, de Eulate RG, Echavarri PD, Mendiroz JA (2011) Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neuro-Oncol 102:105–113. https://doi.org/10.1007/s11060-010-0296-4 CrossRef

30.

Saito K, Hirai T, Takeshima H, Kadota Y, Yamashita S, Ivanova A, Yokogami K (2017) Genetic factors affecting intraoperative 5-aminolevulinic acid-induced fluorescence of diffuse gliomas. Radiol Oncol 51:142–150. https://doi.org/10.1515/raon-2017-0019 CrossRefPubMedPubMedCentral

31.

Roberts DW, Valdes PA, Harris BT, Fontaine KM, Hartov A, Fan X, Ji S, Lollis SS, Pogue BW, Leblond F, Tosteson TD, Wilson BC, Paulsen KD (2011) Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 114:595–603. https://doi.org/10.3171/2010.2.JNS091322 CrossRefPubMed

32.

Johansson A, Palte G, Schnell O, Tonn JC, Herms J, Stepp H (2010) 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol 86:1373–1378. https://doi.org/10.1111/j.1751-1097.2010.00799.x CrossRefPubMed

33.

Kim A, Khurana M, Moriyama Y, Wilson BC (2010) Quantification of in vivo fluorescence decoupled from the effects of tissue optical properties using fiber-optic spectroscopy measurements. J Biomed Opt. https://doi.org/10.1117/1.3523616 CrossRefPubMedPubMedCentral

34.

Valdes PA, Leblond F, Kim A, Harris BT, Wilson BC, Fan XY, Tosteson TD, Hartov A, Ji SB, Erkmen K, Simmons NE, Paulsen KD, Roberts DW (2011) Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg 115:11–17. https://doi.org/10.3171/2011.2.Jns101451 CrossRefPubMedPubMedCentral

35.

Utsuki S, Oka H, Sato S, Suzuki S, Shimizu S, Tanaka S, Fujii K (2006) Possibility of using laser spectroscopy for the intraoperative detection of nonfluorescing brain tumors and the boundaries of brain tumor infiltrates—technical note. J Neurosurg 104:618–620. https://doi.org/10.3171/jns.2006.104.4.618 CrossRefPubMed

36.

Valdes PA, Kim A, Brantsch M, Niu C, Moses ZB, Tosteson TD, Wilson BC, Paulsen KD, Roberts DW, Harris BT (2011) Delta-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro-oncology 13:846–856. https://doi.org/10.1093/neuonc/nor086 CrossRefPubMedPubMedCentral

Title: 5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas
Authors: Muhammad Omar Chohan
Mitchel S. Berger
Publication date: 01-02-2019
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2956-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience

5-aminolevulinic acid induced protoporphyrin IX (ALA-PpIX) fluorescence guidance in meningioma surgery

Effects of 5-ALA dose on resection of glioblastoma

5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas

Visualization technologies for 5-ALA-based fluorescence-guided surgeries

Fluorescence guided surgery by 5-ALA and intraoperative MRI in high grade glioma: a systematic review